California has become the first state in the US to ban use of a hazardous phthalate from IV bags and tubing with a measure that reflects growing concern about health effects on vulnerable patients and creates new urgency for device makers to pivot to friendlier alternatives.
California To Ban DEHP In IV Bags, Tubing With Phased Compliance Deadlines
California’s Toxic-Free Medical Devices Act to prohibit use of di-2-ethylhexyl phthalate in IV bags and tubing, now headed to Gov. Gavin Newsom’s desk, has broad support from lawmakers and a lack of opposition from industry at this stage. Pennsylvania is considering a similar bill, but with differences that could portend a patchwork legislation problem ahead in the US.

More from Legislation
Medical devices, diagnostics, and equipment face tariffs announced by President Donald Trump, despite industry pleas for exemption. The tariffs, ranging from 10%-49%, impact most countries trading with the US, potentially hindering innovation and increasing costs in the medtech sector.
Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. Representatives were left wondering if user fee programs would continue, even if reauthorized.
AdvaMed’s top priorities for the 119th Congress include modernizing US Medicare services and expanding patients’ access to the latest medical technologies.
A federal judge in Texas delivered what is most likely a fatal blow to the US FDA’s final rule, which would have regulated lab-developed tests as medical devices.
More from Policy & Regulation
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
Some employees were not impressed with FDA Commissioner Martin Makary's first speech to the agency staff, saying he did not seem to understand the agency's mission.
Swiss medtech exporters seek urgent diplomatic action from the Swiss Federal Council in a bid to overturn the 2 April US decision to put tariffs on goods imports.